125 related articles for article (PubMed ID: 17556315)
1. Intravenous versus oral iron supplementation in peritoneal dialysis patients.
Johnson DW
Perit Dial Int; 2007 Jun; 27 Suppl 2():S255-60. PubMed ID: 17556315
[TBL] [Abstract][Full Text] [Related]
2. Oral versus intravenous iron supplementation in peritoneal dialysis patients.
Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
Perit Dial Int; 2001; 21 Suppl 3():S231-5. PubMed ID: 11887827
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial).
Barraclough KA; Noble E; Leary D; Brown F; Hawley CM; Campbell SB; Isbel NM; Mudge DW; van Eps CL; Sturtevant JM; Johnson DW
BMC Nephrol; 2009 Jul; 10():20. PubMed ID: 19635169
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial.
Barraclough KA; Brown F; Hawley CM; Leary D; Noble E; Campbell SB; Isbel NM; Mudge DW; van Eps CL; Johnson DW
Nephrol Dial Transplant; 2012 Nov; 27(11):4146-53. PubMed ID: 22962411
[TBL] [Abstract][Full Text] [Related]
5. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients.
Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
Nephrol Dial Transplant; 2001 Sep; 16(9):1879-84. PubMed ID: 11522873
[TBL] [Abstract][Full Text] [Related]
6. [Anemia in peritoneal dialysis patients].
Lausević M; Nesić V; Jovanović N; Stojimirović B
Srp Arh Celok Lek; 2006; 134(3-4):133-7. PubMed ID: 16915754
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin.
Stoves J; Inglis H; Newstead CG
Nephrol Dial Transplant; 2001 May; 16(5):967-74. PubMed ID: 11328902
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.
Li H; Wang SX
Perit Dial Int; 2008; 28(2):149-54. PubMed ID: 18332450
[TBL] [Abstract][Full Text] [Related]
9. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Iron status and iron supplementation in peritoneal dialysis patients.
Vychytil A; Haag-Weber M
Kidney Int Suppl; 1999 Mar; 69():S71-8. PubMed ID: 10084290
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
[TBL] [Abstract][Full Text] [Related]
14. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
Johnson CA; Rosowski E; Zimmerman SW
Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
[TBL] [Abstract][Full Text] [Related]
15. Oral iron for patients receiving dialysis: what is the evidence?
Hodson EM; Craig JC
Semin Dial; 2014; 27(1):8-10. PubMed ID: 24400800
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
18. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
Macdougall IC
Curr Med Res Opin; 2010 Feb; 26(2):473-82. PubMed ID: 20014980
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Iron Does Not Augment the Hemoglobin Mass Response to Simulated Hypoxia.
Garvican-Lewis LA; Vuong VL; Govus AD; Peeling P; Jung G; Nemeth E; Hughes D; Lovell G; Eichner D; Gore CJ
Med Sci Sports Exerc; 2018 Aug; 50(8):1669-1678. PubMed ID: 29538179
[TBL] [Abstract][Full Text] [Related]
20. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial.
Ahsan N
Adv Perit Dial; 2000; 16():80-4. PubMed ID: 11045266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
